- Home
- ABVX vs CORT Comparison
ABVX vs CORT Comparison
Compare ABVX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVX
- CORT
- Stock Information
- Founded
- ABVX 2013
- CORT 1998
- Country
- ABVX France
- CORT United States
- Employees
- ABVX N/A
- CORT N/A
- Industry
- ABVX
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- ABVX
- CORT Health Care
- Exchange
- ABVX Nasdaq
- CORT Nasdaq
- Market Cap
- ABVX 6.7B
- CORT 7.6B
- IPO Year
- ABVX N/A
- CORT N/A
- Fundamental
- Price
- ABVX $104.29
- CORT $72.26
- Analyst Decision
- ABVX Strong Buy
- CORT Strong Buy
- Analyst Count
- ABVX 10
- CORT 4
- Target Price
- ABVX $103.80
- CORT $139.00
- AVG Volume (30 Days)
- ABVX 1.1M
- CORT 949.8K
- Earning Date
- ABVX 08-11-2025
- CORT 11-04-2025
- Dividend Yield
- ABVX N/A
- CORT N/A
- EPS Growth
- ABVX N/A
- CORT N/A
- EPS
- ABVX N/A
- CORT 1.11
- Revenue
- ABVX $7,073,400.00
- CORT $716,080,000.00
- Revenue This Year
- ABVX $4.44
- CORT $28.85
- Revenue Next Year
- ABVX N/A
- CORT $34.98
- P/E Ratio
- ABVX N/A
- CORT $64.65
- Revenue Growth
- ABVX N/A
- CORT 25.71
- 52 Week Low
- ABVX $4.77
- CORT $42.01
- 52 Week High
- ABVX $98.94
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- ABVX 74.51
- CORT 37.81
- Support Level
- ABVX $90.85
- CORT $70.89
- Resistance Level
- ABVX $94.26
- CORT $73.09
- Average True Range (ATR)
- ABVX 3.46
- CORT 3.23
- MACD
- ABVX 0.17
- CORT -0.95
- Stochastic Oscillator
- ABVX 96.24
- CORT 19.70
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.